Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are usually cheap for a reason — five cents for a piece of fruit may seem like a great deal until you find out it’s rotten.
Identifying genuine bargains from value traps is something many investors struggle with, which is why we started StockStory - to help you find the best companies. Keeping that in mind, here are three value stocks facing an uphill battle and some other investments you should look into instead.
ICF International (ICFI)
Forward P/E Ratio: 9.6x
Operating at the intersection of policy, technology, and implementation for over five decades, ICF International (NASDAQ: ICFI) provides professional consulting services and technology solutions to government agencies and commercial clients across energy, health, environment, and security sectors.
Why Should You Sell ICFI?
- Products and services are facing significant end-market challenges during this cycle as sales have declined by 3.9% annually over the last two years
- Demand cratered as it couldn’t win new orders over the past two years, leading to an average 6.1% decline in its backlog
- Earnings per share have dipped by 4% annually over the past two years, which is concerning because stock prices follow EPS over the long term
ICF International is trading at $68.32 per share, or 9.6x forward P/E. Read our free research report to see why you should think twice about including ICFI in your portfolio.
Bristol-Myers Squibb (BMY)
Forward P/E Ratio: 8.9x
With roots dating back to 1887 and a transformative merger in 1989 that gave the company its current name, Bristol-Myers Squibb (NYSE: BMY) discovers, develops, and markets prescription medications for serious diseases including cancer, blood disorders, immunological conditions, and cardiovascular diseases.
Why Is BMY Not Exciting?
- Sales stagnated over the last two years and signal the need for new growth strategies
- Projected sales decline of 4.1% for the next 12 months points to an even tougher demand environment ahead
- Earnings per share fell by 1.7% annually over the last five years while its revenue grew, showing its incremental sales were much less profitable
Bristol-Myers Squibb’s stock price of $54.90 implies a valuation ratio of 8.9x forward P/E. Dive into our free research report to see why there are better opportunities than BMY.
MGIC Investment (MTG)
Forward P/B Ratio: 1x
Founded in 1957 when the modern mortgage insurance industry was in its infancy, MGIC Investment (NYSE: MTG) provides private mortgage insurance that protects lenders when homebuyers default on their loans, enabling borrowers to purchase homes with smaller down payments.
Why Does MTG Worry Us?
- Net premiums earned contracted by 1.2% annually over the last five years, showing unfavorable market dynamics this cycle
- Sales are projected to tank by 1.3% over the next 12 months as demand evaporates
- Earnings growth underperformed the sector average over the last two years as its EPS grew by just 9.4% annually
At $24.91 per share, MGIC Investment trades at 1x forward P/B. Check out our free in-depth research report to learn more about why MTG doesn’t pass our bar.
High-Quality Stocks for All Market Conditions
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.
